RenovoRx (RNXT) Projected to Post Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is anticipated to announce its Q3 2025 results after the market closes on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.25 million. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Stock Performance

RenovoRx stock opened at $1.00 on Tuesday. The firm has a market cap of $36.51 million, a PE ratio of -2.62 and a beta of 1.29. The firm’s 50 day moving average price is $1.17 and its two-hundred day moving average price is $1.19. RenovoRx has a twelve month low of $0.75 and a twelve month high of $1.69.

Institutional Trading of RenovoRx

An institutional investor recently bought a new position in RenovoRx stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of RenovoRx, Inc. (NASDAQ:RNXT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 74,596 shares of the company’s stock, valued at approximately $98,000. Northwestern Mutual Wealth Management Co. owned about 0.20% of RenovoRx as of its most recent filing with the Securities and Exchange Commission. 3.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Ascendiant Capital Markets boosted their price target on shares of RenovoRx from $11.50 to $12.00 and gave the company a “buy” rating in a report on Monday, August 25th. Wall Street Zen downgraded RenovoRx from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RenovoRx in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, RenovoRx has an average rating of “Hold” and a consensus price target of $7.50.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.